With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

What have we accomplished for schizophrenia patients since the introduction of
chlorpromazine in 1952 (1)? Have we really made a difference in the outcome of …

Cognitive impairments are a core and persistent characteristic of schizophrenia with
implications for daily functioning. These show only limited response to antipsychotic …

Background Schizophrenia (SCZ) and bipolar disorder (BIP) are debilitating
neuropsychiatric disorders, collectively affecting 2% of the world's population. Recognizing …

Participants with schizophrenia (SCZ) and bipolar disorder (BD) have challenges in self-
evaluation of their cognitive and functional abilities, referred to as introspective accuracy …

Identifying genetic contributors to cognitive impairments in psychosis-spectrum disorders
can advance understanding of disease pathophysiology. Although CNS medications are …

Neurocognitive variability exists within the schizophrenia spectrum disorder (SSD)
population, with subgroups performing at the same level as healthy samples Here we study …

Cognitive impairment is a predictor of disability across different neuropsychiatric conditions,
and cognitive abilities are also strongly related to educational attainment and indices of life …

Although issues associated with returning individual research results to study participants
have been well explored, these issues have been less thoroughly investigated in vulnerable …

Background Cognitive dysfunction is a core manifestation of schizophrenia and one of the
best predictors of long‐term disability. Genes increasing risk for schizophrenia may partly act …